Our Leadership Team

Xingjuan (Jane) Chao, Ph.D. is a co-founder of our company and has served as our Chief Executive Officer since October 2014, as a member of our board of directors since August 2015, and as our President since July 2016. Prior to joining Ceribell, Dr. Chao served as Principal Manager of Portfolio Management Strategy at Genentech, Inc., a biotechnology company, from June 2014 until August 2015, and as Senior Strategy Manager at Novartis AG, a pharmaceutical company, from January 2013 until June 2014. Dr. Chao previously served as a management consultant at McKinsey & Company, a consulting company, from July 2007 until January 2013. Dr. Chao has served on the board of directors of Magnus Medical, Inc., a medical equipment company, since June 2026, having previously served on its board from November 2021 to February 2025. Dr. Chao received a B.S. in chemistry from Peking University, a Ph.D. in biophysics from Cornell University, and completed a postdoctoral fellowship at the University of California, San Francisco.

Raymond Woo, Ph.D.has served as our Chief Technology Officer since February 2017, and previously served as our Vice President of Engineering from June 2016 until February 2017. Prior to joining our company, Dr. Woo held various roles at OptiMedica Corporation, an ophthalmic device company, from September 2011 until its acquisition by Abbott Medical Optics, Inc. (“Abbott”), a manufacturer of ophthalmic care products, in 2013. Dr. Woo subsequently held various roles at Abbott from August 2013 until May 2016, including most recently as the Global Head, Femtosecond Laser R&D. Previously, Dr. Woo served as Senior Engineer at Exponent Failure Analysis Associates, an engineering and scientific consulting firm, from January 2009 until September 2011. Dr. Woo received a B.S. in electrical engineering and computer science from Duke University and a Ph.D. in electrical engineering from Stanford University.

Scott Blumberg has served as our Chief Financial Officer since April 2020. Prior to joining the company, Mr. Blumberg served as Managing Advisor at Venture Forward Advisory Services, an advisory firm, from June 2014 until December 2020, as Director of Business Development at IDEV Technologies, Inc., a medical device company, from February 2009 until January 2014, as an Analyst at Bay City Capital, an investment firm, from July 2006 until January 2009, and as an Investment Banking Analyst at Bank of America from June 2004 until June 2006. Mr. Blumberg received an A.B. in economics from Dartmouth College.

Sean Manni joins Ceribell after more than 25 years in the healthcare industry. Most recently, he served as Vice President, North America Sales at Omnicell, a healthcare service company. Mr. Manni’s high-impact go-to-market strategies helped Omnicell achieve 4x growth in annual revenue during his tenure there. While at Omnicell , Mr. Manni oversaw the growth of a large sales organization and transitioned the business to a SaaS-oriented model, fueling company expansion to become a leader in its space. Previously, Mr. Manni served at several healthcare companies including Stinger Medical, Arrow International, and GlaxoSmithKline plc. Throughout his career, Mr. Manni has successfully driven transformative change by engaging with national health systems, spearheading commercial innovation, and maintaining a steadfast commitment to a people-first strategy. Mr. Manni obtained his Bachelor’s degree from East Stroudsburg University in Pennsylvania.

Louisa Daniels has served as General Counsel of Ceribell since August 2023. Ms. Daniels has been practicing law for over 30 years and oversees all legal and compliance matters for Ceribell. Ms. Daniels has a track record of successful execution with both private and public life sciences and technology companies, including in connection with commercial product launches, and resolution of complex litigation, compliance and other corporate matters. Ms. Daniels has worked for several global biopharmaceutical companies in her career. Before Ceribell, Ms. Daniels was Chief Legal Officer and Chief Compliance Officer for Recursion Pharmaceuticals, a clinical-stage company focused on AI-enabled drug discovery, which she helped take public in April 2021. From 2008 to 2021, Ms. Daniels served as Vice President and Assistant General Counsel at Pfizer, where she held various management positions including Chief Counsel for Global Product Development; Global Commercial Operations, Strategy & Portfolio Management; and both BioTherapeutics and PharmaTherapeutics R&D. Prior to Pfizer, she worked as in-house counsel at Elan Pharmaceuticals and Tularik Inc., which was acquired by Amgen during her tenure. Ms. Daniels received a B.A. and J.D. from the University of California, Berkeley and an M.B.A. from the University of California, Irvine (Paul Merage School of Business).

Baharan Kamousi, Ceribell’s SVP of Data Science, joined Ceribell in 2017 with over 15 years of algorithm design experience for various medical applications spanning from Brain-Computer Interface, bioelectricity and audiometry to diagnostic and treatment algorithms for chronic diseases such as cardiac arrhythmias and heart failure, chronic pain, urinary incontinence and brain stimulation. She started her career at St. Jude Medical in the clinical systems engineering department where she gained extensive experience in all aspects of medical device and algorithms product lifecycle for various cardiovascular and neuromodulation applications and later joined a start-up company, Element Science, to design a machine learning algorithm for a wearable cardioverter defibrillator for patients at high risk of sudden cardiac arrest. Baharan holds a Bachelor’s degree in Electrical Engineering from Sharif University of Technology and has completed her Master’s and Ph.D. programs at University of Minnesota ECE department and as a visiting researcher at Stanford University, School of Medicine.

Mr. Price is an industry veteran who brings to Ceribell more than 25 years of
experience in the medical device industry, including marketing leadership
roles at Medtronic and Abbott. In his new role at Ceribell, he will leverage
his expertise in market development, product portfolio planning, business
development, health economics, reimbursement and sales. He most
recently served as Chief Marketing Officer of VitalConnect, and previously
held sales and marketing leadership roles with LivaNova, St. Jude Medical,
WebMD and Guidant Corporation, where he drove multiple incremental
product launches and disruptive therapy platforms across many specialties
including neurology, cardiology, urology and gynecology. Mr. Price holds a
Master of Business Administration degree from the University of Minnesota
Carlson School of Management and a Bachelor of Science in Organizational
Leadership and Industrial Technology from Purdue University.

Dan Rogy, Ceribell’s SVP of Operation, has over 25 years of medical equipment and disposable device Operations and R&D management experience. He led the R&D and Operation Teams at Outset Medical to commercialize a novel Hemodialysis system. Dan was General Manager at Abbott Laboratories, after the acquisition of OptiMedica, where he was responsible for all medical capital equipment and disposable device operations. Previously he was Director of R&D at Adiana, acquired by Cytyc Corporation, leading the development and manufacturing of a complex disposable implant and RF Generator. He also held operational management roles at Eli Lilly/Guidant Corporation supplying equipment to manufacturing sites in England, Ireland and the US. Dan has multiple patents for disposable and implant devices and completed his business degree at Illinois Central College.

Dave Foehr, Ceribell’s SVP of Finance, has over 20 years of experience in the healthcare industry. Before joining Ceribell, Dave was VP of Finance and Corporate Controller at Fluidigm Corporation, a biotechnology company based in South San Francisco. Prior to Fluidigm, Dave held various Finance roles at Stryker Endoscopy and Johnson & Johnson. Dave began his career at Chevron as part of their MBA Development Program. Dave holds an MBA in Finance & Corporate Accounting from the University of Rochester and a Bachelor of Chemical Engineering from Villanova University.

Alex Grant, Ceribell’s VP of Engineering, joined the company in 2015 to work on developing and commercializing its first EEG system. Before joining Ceribell, Alex’s academic research focused on development of novel non-invasive medical imaging technologies, including NIR spectroscopy and PET/MRI for cancer detection and staging. Alex holds a Ph.D. and Master’s degree in Bioengineering from Stanford University and a Bachelor’s degree in Physics from UC Irvine.